Biological functions of CDK5 and potential CDK5 targeted clinical treatments.

Authors

Alison Shupp, Thomas Jefferson UniversityFollow
Mathew C. Casimiro, Pennsylvania Cancer and Regenerative Medicine Research CenterFollow
Richard G. Pestell, Pennsylvania Cancer and Regenerative Medicine Research CenterFollow

Document Type

Article

Publication Date

1-6-2017

Comments

This article has been peer reviewed. It is the author’s final published version in Oncotarget.

Volume 8, Issue 10, January 2017, Pages 17373-17382.

The published version is available at DOI: 10.18632/oncotarget.14538. Copyright © Shupp et al.

Abstract

Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit. For most CDKs, activation by a cyclin occurs through association and phosphorylation of the CDK's T-loop. CDK5 is unusual because it is not typically activated upon binding with a cyclin and does not require T-loop phosphorylation for activation, even though it has high amino acid sequence homology with other CDKs. While it was previously thought that CDK5 only interacted with p35 or p39 and their cleaved counterparts, Recent evidence suggests that CDK5 can interact with certain cylins, amongst other proteins, which modulate CDK5 activity levels. This review discusses recent findings of molecular interactions that regulate CDK5 activity and CDK5 associated pathways that are implicated in various diseases. Also covered herein is the growing body of evidence for CDK5 in contributing to the onset and progression of tumorigenesis.

Recommended Citation

Shupp, Alison; Casimiro, Mathew C.; and Pestell, Richard G., "Biological functions of CDK5 and potential CDK5 targeted clinical treatments." (2017). Department of Cancer Biology Faculty Papers. Paper 111.
https://jdc.jefferson.edu/cbfp/111

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

PubMed ID

28077789